Juvista failure rocks Renovo but Shire stays silent
This article was originally published in Scrip
Executive Summary
In a major blow to the company and the UK biotech sector, Renovo saw its share price crash on news that its lead anti-scarring product Juvista completely failed in its first Phase III trial.